{"nctId":"NCT00358436","briefTitle":"Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)","startDateStruct":{"date":"2006-08"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"count":804,"armGroups":[{"label":"Aclidinium 200 μg once-daily","type":"EXPERIMENTAL","interventionNames":["Drug: Aclidinium bromide"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Aclidinium bromide","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Males and females aged ≥ 40 years with a clinical diagnosis of moderate to severe stable COPD\n\nExclusion Criteria:\n\n* History or current diagnosis of asthma, recent respiratory tract infection or acute COPD exacerbation, life expectancy of less than 1 year, known symptomatic prostatic hypertrophy, bladder neck obstruction or narrow-angle glaucoma","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Trough FEV1 (L) at 28 Weeks on Treatment","description":"Trough FEV1 (mean FEV1 value of the two highest FEV1 readings measured at 23 and 24 hours after inhalation) at 28 weeks","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.220","spread":"0.008"},{"groupId":"OG001","value":"1.162","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Time to First Moderate or Severe COPD Exacerbation at 52 Weeks on Treatment","description":"Time to first moderate or severe exacerbation: Increase of COPD symptoms during at least 2 consecutive days, treated with antibiotics and/or systemic corticosteroids or an increase in dose of systemic corticosteroids, or leading to hospitalisation.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Achieved at Least a 4-unit Decrease From Baseline in the SGRQ Total Score at 52 Weeks on Treatment","description":"Percentage of patients who achieved a clinically relevant improvement in health-related quality of life at 52 weeks, as measured by at least a 4-unit decrease from baseline in St George's Respiratory Questionnaire (SGRQ) total score","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.0","spread":null},{"groupId":"OG001","value":"32.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.0","spread":null},{"groupId":"OG001","value":"67.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Trough FEV1 (L) at 12 Weeks on Treatment","description":"Trough FEV1 (mean FEV1 value of the two highest FEV1 readings measured at 23 and 24 hours after inhalation) at 12 weeks","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.233","spread":"0.007"},{"groupId":"OG001","value":"1.171","spread":"0.012"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":62,"n":600},"commonTop":["Headache","Nasopharyngitis","Upper respiratory tract infection","Back pain","Diarrhoea"]}}}